It could be the first anti-PD-1 therapy in Europe, if approved.
Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Additional regulatory filings in other countries outside of Europe are planned by the end of 2014.
“With the five-year survival rate for patients with advanced melanoma at less than 20 percent, there remains a need to offer patients additional options,” said Dr. Roy Baynes, senior vice president, clinical development, Merck Research Laboratories. “We are pleased to have regulatory applications under review in the United States and Europe as we work toward bringing pembrolizumab to patients around the world.”
Source: MarketWatch
NCCN Launches Pilot Project Aiming to Measure, Implement Health Equity in Cancer Care Practices
February 4th 2023Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Study Suggests MRI Is the Best Breast Cancer Screening Modality for Dense Breasts
February 1st 2023A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.
Read More
Interstitial Lung Abnormalities Impact OS in NSCLC Patients Receiving CRT, Adjuvant Durvalumab
January 19th 2023Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512